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Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically
reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However,
increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines
covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine
(PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A.
After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated
that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs),
mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal
diseases in children based on previous studies.
1. Introduction
The heptavalent pneumococcal conjugate vaccine (PCV7)
schedule in the pediatric population has significantly reduced
the incidence of pneumococcal diseases in both vaccinated
children and unvaccinated individuals of all ages [1]. This led
to the conclusion that PCV7 not only was highly effective
in vaccinated children but also could induce herd immunity,
which limited the spread of pneumococcal diseases in the
population living in the same geographic areas as the vacci-
nated children. For example, the US CDC has reported up
to about 90% reduction of the incidence of invasive pneumo-
coccal diseases (IPDs) caused by Streptococcus pneumoniae in
young children with the introduction of PCV7 [2]. After the
applications of PCV7, a significant decline in pneumococcal
mucosal diseases such as acute otitis media (AOM) and
nonbacteremic pneumonia has also been reportedworldwide
in children and in adults, especially in the elderly [3, 4].
While the incidence of pneumococcal diseases caused by
PCV7 serotypes continued to decline with the introduction
of PCV7, increased incidence of infections caused by non-
PCV7 serotypes, mainly serotypes 19A, 7F, 6A, and 6C,
has been reported by several groups [1], which reduced
the global efficacy of PCV7 against pneumococcal diseases
[5–7]. To overcome this problem, a new vaccine covering
more serotypes, especially the emerging serotypes, has been
developed. The 13-valent pneumococcal conjugate vaccine
(PCV13) currently covers the most serotypes, including 7
PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and six
additional serotypes 1, 3, 5, 6A, 7F, and 19A. The carrier
protein used in PCV13 remains the same as that in PCV7.
Thus, all the capsular polysaccharides of the 13 serotypes
included in PCV13were conjugatedwith the nontoxicmutant
of diphtheria toxin CRM 197. PCV13 was licensed to replace
PCV7 in 2010 for children between 6 weeks and 5 years of age
in the United States of America and the European Union [8,
9]. PCV13 was licensed on the basis of immunogenicity data
alone through a putative protection correlate derived from
pooled immunogenicity data and results of pediatric efficacy
trials on PCV7 [10]. Therefore, assessments of the protection
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effectiveness of PCV13 have drawn great interest immediately
after it was licensed. Given the limitations of immunogenicity
data in predicting protective efficacy conferred by vaccines
[11], postmarket surveillance and effectiveness studies are
highlighted for evaluating newly developed vaccines, par-
ticularly those with additional serotypes such as PCV13.
Therefore, a number of studies have monitored the incidence
of pneumococcal diseases in PCV13-vaccinated and PCV13-
unvaccinated population and the circulation of pneumo-
coccal serotypes in both patients and healthy subjects. In
this review, we evaluated the impacts of PCV13 in younger
children based on previous studies on the effects of PCV13 on
the incidence of invasive pneumococcal diseases, pneumonia,
acute otitis media (AOM), and nasopharyngeal carriage. We
searched PubMed for eligible studies published from January
2010 to August 2014 using the key words, “PCV13” or “13-
valent pneumococcal conjugate vaccine” and “children” or
“pediatric.” Only articles published in English were included
in the evaluation.
2. Invasive Pneumococcal Disease (IPD)
Most studies on the effectiveness of PCV13 against IPD
have demonstrated that PCV13 introduction has significantly
reduced the incidence of IPD in both vaccinated children and
unvaccinated population compared to the previous PCV7
applications, and the results were independent of countries,
the scheme of PCV13 administration [12–18]. However, dif-
ferent effectiveness regarding the 6 additional serotypes has
been reported.
The traditional 3 + 1 scheme of administration at 2, 4,
6, and 12 months was used in the USA. Recently, the US
Centers for Disease Control and Prevention (CDC) have
evaluated the impacts of PCV13 on IPD incidence through
an active population-based surveillance in 10 regions around
the country [12]. Continuous reduction of IPD cases due to
new serotypes included in PCV13 has been observed in all
groups of different ages during the first threemonths after the
introduction of PCV13 in 2010. Particularly, 93%, 75%, 72%,
62%, and 58% reductions of the incidence of IPD caused by
serotypes 1, 3, 5, 7F, and 19A were observed for subjects of <5,
5–17, 18–49, 50–64, and >65 years of age, respectively, in 2012
and 2013. However, analysis of the incidence of IPD caused
by non-PCV13 serotypes revealed a possible early evidence
of serotype replacement among adults of 18–49 and 50–64
years. In these two groups, incidence of IPD caused by non-
PCV13 serotypes in 2012-2013 was 13% and 26% that were
higher than expected when PCV13 was not available. This
had only a marginal impact on the global effectiveness of
PCV13 because of a significant reduction (about 30,000 cases)
in overall IPD incidence and mortality (3,000 deaths) in all
groups of different ages. The most significant reduction of
IPD incidence was observed in the group of children aged <5
years for whom the IPD incidence was reduced by 64% in
2012-2013 compared to the time when PCV13 is not available.
On the contrary, reduction in mortality was more important
in adults, particularly in those older than 50 years.
It has been reported that the protective effectiveness of
each serotype included in PCV13 was different. For example,
it was 100% for serotype 7F, 76–96% for serotype 19A, and
13–93% for serotype 3. In addition, PCV13 administration
was significantly effective in a special population, the Alaska
Native people who are under higher risk of IPD than
the general population of the USA. Singleton et al. have
followed a total of 3,714 Alaska Native children (<5 years of
age) who received the PCV13 vaccination between January
2009 and August 2011 according to the US recommenda-
tions [13]. They found only 9 cases of IPD including 7
cases caused by PCV13 serotypes between 2009 and 2011
(106.7/100,000/year), whereas 52 IPD cases including 31 cases
caused byPCV13 serotypeswere diagnosed between 2005 and
2008 (399.0/100,000/year; 𝑃 < 0.001). In addition, no IPD
cases were reported among PCV13 recipients during 2009–
2011.
The 3 + 1 schedule was also applied in Canada and led
to highly protective effectiveness. After the introduction of
PCV13 in Canada, the incidence of IPD in children <5 years
of age declined from 18.0 to 14.2 cases per 100,000 population
in the period of 2010–2012 [14]. Specifically, PCV13 serotypes
declined significantly from 66% (224/339) to 41% (101/244;
𝑃 < 0.001) in children <5 years of age and from 54%
(1,262/2,360) to 43% (1,006/2,353; 𝑃 < 0.001) in children
≥5 years of age. Serotypes 19A, 7F, 3, and 22F were the
most common serotypes in IPD cases reported in 2012. The
IPD caused by serotypes 19A and 7F declined from 19% to
14% (𝑃 < 0.001) and 7F from 14% to 12% (𝑃 = 0.04),
respectively, during 2010–2012. IPD caused by serotypes 22F
and 3 increased from 7% to 11% (𝑃 < 0.001) and 7% to 10%
in children of <5 years of age (𝑃 = 0.22), respectively, during
2010–2012 [14].
The 2 + 1 schedule (PCV13 administration at 2, 4, and
12-13 months) was started in England, Wales, and Northern
Ireland on April 1, 2010, to replace the previous PCV7
schedule. According to the epidemiological data in the Public
Health of England, 706 IPD cases were reported during
April 2010 and October 2013, including 30 caused by PCV7
serotypes, 292 caused by the additional 6 serotypes of PCV13
or serotype 6C, and 414 caused by non-PCV13 serotypes [15].
Regarding the vaccination status of the studied children, it
was reported that the PCV13 effectiveness after 2 doses in
the first year or one dose after 12 months was 75% (95%
confidence interval [CI], 58%–84%). The effectiveness was
90% (95% CI, 34%–98%) for the PCV7 serotypes and 73%
(95% CI, 55%–84%) for 4 of the 6 additional serotypes of
PCV13. In addition, the vaccine effectiveness of serotype 3
was not significantly different and the vaccine effectiveness of
serotype 5 could not be analyzed because no case of infection
due to this serotype was observed during the studying period
[15].
InDenmark, a nationwide population-based cohort study
was conducted to evaluate the dynamic changes of IPD
incidence during three periods, the baseline (2000–2007),
the PCV7 period (2008–2010), and the PCV13 period (2011–
2013) [16]. In the study, a 21% reduction (95% CI, 17%–
25%) of IPD incidence in the whole population and a 71%
reduction (95% CI, 62%–79%) of IPD incidence in children
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aged <2 years were reported after PCV13 introduction. In
addition, a 28% reduction (95% CI, 18%–37%) of the 30-
day mortality due to IPD was observed, decreasing from 3.4
deaths (95% CI, 3.2%–3.6%) to 2.4 (95% CI, 2.2%–2.7%) per
100,000 population after PCV13 introduction. The decline of
mortality was observed in all groups of different ages and
mainly in the nonvaccinated population, which is consistent
with the report from the USA [16]. However, for serotypes
1 and 3, there were no significant changes in incidence
beyond what would be expected from the natural cyclical
patterns [16]. On the contrary, for serotype 19A for which
a significant increase in disease incidence following PCV7
has been reported, the introduction of PCV13 was followed
by a significant decline in the number of the cases towards
baseline pre-PCV7 levels.
The high effectiveness of PCV13 (the scheme 2 + 1) was
also reported in Israel by Ben-Shimol et al. based on a
prospective surveillance of IPD during July 2004 and June
2013 [17]. The incidence of IPD caused by PCV7 6A serotype
during the PCV13 application period decreased by 95%
(incidence rate ratio [IRR] = 0.05; 95% CI, 0.03%–0.09%)
including 90% in the PCV7 period and further 5% in the
PCV13 period among the 2,670 IPD cases compared to the
pre-PCV13 period. The incidence of IPD caused by the 5
additional PCV13 serotypes 1, 3, 5, 7F, and 19A increased
initially by 47% but subsequently decreased by 79%, resulting
in an overall 70% reduction during the entire study period
(IRR = 0.30; 95% CI, 0.21%–0.44%). In total, a 63% reduction
of IPD caused by all serotypes was observed in children aged
<5 years (69% and 48% in children <2 and 2–4 years of
age, resp.). However, a certain degree of replacement was
evidenced because a twofold increase of IPD caused by non-
PCV13 serotypes was found (IRR = 2.43; 95% CI, 1.73%–
3.66%).Themost commonly increased serotypes were 12F, 15
B/C, and 33F [17].
On the contrary, negative replacement phenomenon was
reported in a study conducted by Levy et al., in which
1,406 cases of pneumococcal meningitis were reported in
2001–2012 [18]. Three years after the PCV13 administration,
the number of pneumococcal meningitis cases significantly
decreased by 27.4% (𝑃 = 0.041). Specifically, a 28.2% (𝑃 =
0.039) reduction was reported for children <2 years of age.
Pneumococcal meningitis caused by the 6 additional PCV13
types decreased by 66.7%, but the number of cases due to
nonvaccine serotypes remained stable. In 2012, 67.6% of cases
were caused by the non-PCV13 serotypes including 12F (15%),
24F (15%), 22F (7%), and 15B/C (7%).
3. Pneumonia
A marked reduction of incidence of community acquired
pneumonia (CAP) mainly in vaccinated children <2 years
after the implementation of PCV7 has been reported in
a number of countries [19, 20]. However, a number of
worldwide studies have reported a significant increase of the
incidence of severe CAP cases (i.e., empyema) caused by
PCV13 serotypes 1, 3, 5, 7F, and 19A during the large scale
administration of PCV7 [21]. Therefore, it was hypothesized
that PCV13 could reduce the incidence of CAP in both
vaccinated children and unvaccinated subjects.
This hypothesis was confirmed with the implementation
of PCV13 in a number of countries. In Uruguay, PCV7
(schedule 2 + 1) was applied in 2008 and replaced by PCV13
(schedule 2 + 1) in 2010, and a catch-up immunization with
a single dose of PCV13 was offered to children born between
2005 and 2009. It has been shown that PCV7 and the PCV13
schedules have significantly reduced the incidence of CAP in
children 0–14 years of age compared to the CAP incidence
prior to the vaccination in 2003–2007 and the introduction
of PCV13 had further reduced CAP compared to the CAP
incidence during the PCV7 administration period [22].
Particularly, the global CAP hospitalization rate was reduced
by 78.1% by PCV7 compared to prior vaccination period
and increased to 92.4% after PCV13. In addition, PCV13
introduction was accompanied by a relevant reduction of
the incidence of CAP due to serotypes 1 and 5, which, on
the contrary, increased in the years of PCV7 administration.
However, a significant increase of the total number of CAPs
caused by non-PCV13 serotypes was observed during the
period of 2009–2012 [22].
A PCV13 schedule 3 + 0 (i.e., 3 doses at 2, 4, and 6
months without any booster) was introduced in Nicaragua in
2010. Becker-Dreps et al. compared the rates of pneumonia
hospitalizations and ambulatory visits of CAP between the
prevaccine (2008–2010) and vaccine (2011-2012) periods [23].
They found that the adjusted incidence ratio for all-cause
CAP hospitalization between the vaccine and prevaccine
periods was 0.67 (0.59–0.75) and 0.74 (0.67–0.81) among
infants and 1-year-old children, respectively. The adjusted
incidence ratio for ambulatory visits of CAP was 0.87 (0.75–
1.01) and 0.84 (0.74–0.95) among infants and 1-year-old
children, respectively. The low rates of health facility visits
due to CAP among children of 2–4 years of age and 5–14
years of age were also observed, suggesting a significant herd
immunity effect [23].
The pneumococcal serotypes 1, 3, 5, 7F, and 19A were
the most frequently causes of CAP after the implementation
of PCV7 and the switch from PCV7 to PCV13 in June 2010
in France, where an observational prospective study was
conducted in 8 pediatric emergency departments between
June 2009 andMay 2012CAP [24]. Children between 1month
and 15 years of age were included in this study and the CAP
was confirmed through chest radiography examination. The
incidence of CAP was compared among three periods (1 year
for each period) including a pre-PCV13 (2009-2010), a tran-
sitional (2010-2011), and a post-PCV13 period (2011-2012). A
total of 5,645 children with CAP including 365 and 136 cases
of pleural effusion and pneumococcal laboratory-confirmed
CAP, respectively, were analyzed.While no catch-up program
was performed for children aged 2–5 years, all-causeCAPand
pneumococcal cases decreased by 16% and 63%, respectively
(𝑃 < 0.001), in the post-PCV13 periods compared to the pre-
PCV13 period. Although the highest reduction was seen in
vaccinated children, a significant decrease of CAP incidence
was also observed in older unvaccinated children, confirming
the herd effect induced by pneumococcal conjugate vaccines.
In addition, the number of pleural effusion cases decreased
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by 53% (𝑃 < 0.001) and the number of CAPs caused by
the additional PCV13 serotypes decreased by 74% [24] in the
post-PCV13 period.
4. Acute Otitis Media (AOM)
The introduction of PCV7 immediately reduced the office
visits of AOM by 6%–7.8% and antibiotic prescriptions by
5.7% [25]. PCV7 vaccination had an even more significant
impact on recurrent AOM by reducing tympanostomy tube
placements by 20%–24% [26]. From the point of view of
microbiologists, PCV7 initially induced a significant reduc-
tion of the incidence of pneumococcal AOM caused by the
PCV7 serotypes. However, the incidence of AOM, caused
by non-PCV7 serotypes, particularly serotypes 6A, 6C, and
19A, increased with the reduction of AOM cases caused by
PCV7 serotypes [27, 28]. In addition, PCV13 could signifi-
cantly reduce the nasopharyngeal colonization by emerging
serotypes causingAOM.Therefore, it has been concluded that
PCV13 provided better protective effects against AOM than
PCV7 [29].This conclusionwas confirmed by the prospective
study conducted in Southern Israel by Ben-Shimol et al.
In this study, the effects of PCV7/PCV13 sequential intro-
duction on pneumococcal and overall AOM necessitating
middle ear fluid (MEF) culture in children <2 years of age
were evaluated based on 6,122 AOM cases including 1,893
pneumococcal cases [30]. Compared to the prevaccination
period, the incidence of AOM caused by serotypes PCV7 +
6A and the 5 additional PCV13 serotypes 1, 3, 5, 7F, and 19A
decreased by 96% and 85%, respectively (IRR and 95% CI
= 0.04, 0.02–0.08 and 0.15, 0.07–0.30, resp.). Specifically, in
the PCV7 vaccination period, only the incidence of AOM
caused by PCV7 + 6A serotypes decreased and in the PCV13
vaccination period the incidence ofAOMcaused by serotypes
1, 3, 5, 7F, and 19A decreased along with a further PCV7 + 6A
AOM reduction. A nonsignificant increase of AOPM caused
by non-PCV13 serotypes was observed (IRR = 1.07; 95%
CI, 0.72–1.58). In total, the incidence of all-pneumococcal
and all-cause AOM decreased by 77% and 60% reductions,
respectively [30].
Zhao et al. have evaluated the microbiological charac-
teristics of middle ear effusions of 118 pediatric patients (6
months to 12 years of age) undergoing pressure equalization
tube (PET) placement between August 2012 and April 2013
[31]. A total of 39 middle ear cultures from 29 patients led to
the growth of at least one bacterial pathogen. Among these
patients, 7 only received PCV7, 18 only received PCV13, and
4 received a combination of PCV7 and PCV13. Only one
culture from a child who has received PCV7 was positive
of S. pneumoniae serotype 16. On the contrary, Haemophilus
influenzae andMoraxella catarrhaliswere isolated from 7 and
3 cases, respectively. The limited number of S. pneumoniae
strains isolated from MEF in this study suggests that PCV13
was effective for preventing AOM caused by serotypes cov-
ered by the vaccine. One of the limitations of this study was
that the studied population has previously received antibi-
otics treatment repeatedly; therefore, the bacterial strains
isolated from the patients were not fully associated with the
effectiveness of vaccination of PCV7 and PCV13.
5. Nasopharyngeal Carriage
Nasopharyngeal pneumococcal carriage is considered as a
prerequisite for the development of pneumococcal disease;
therefore, reduction of nasopharyngeal carriage through
PCV7 is also useful for reducing the incidence of pneumo-
coccal infections among vaccinated children, their families,
and the community [32]. In addition,monitoring the changes
of nasopharyngeal carriage induced by PCV13 vaccination
is important for the evaluation of vaccine effectiveness and
monitoring the development of replacement allows us to
predict possible emergence of new serotypes causing pneu-
mococcal diseases.
Cohen et al. have analyzed 943 nasopharyngeal swabs
from children (6 to 24 months of age) with AOM between
October 2010 and March 2011. Among the 943 children
with AOM, 651 received at least 1 dose of PCV13 and 285
received only PCV7 [18]. The overall pneumococcal carriage
and carriage of non-PCV7 serotypes in the PCV13-vaccinated
children were significantly lower than those in children
exclusively vaccinated with PCV7 (53.9% versus 64.6%, 𝑃 =
0.002, and 9.5% versus 20.7%, 𝑃 < 0.0001, resp.). For
serotypes 19A, 7F, and 6C, the pneumococcal carriage rates
were also significantly lower in PCV13-vaccinated patients
than in patients vaccinated only with PCV7 (7.5% versus
15.4%, 𝑃 < 0.001, 0.5% versus 2.8%, 𝑃 = 0.002, and 3.7%
versus 8.4%, 𝑃 = 0.003, resp.). Analyses of the other new
serotypes included in PCV13were not available due to the low
number of cases identified in the study.
A study on the surveillance of pneumococcal carriage in
children<60monthswas conducted in July 2010 at a pediatric
center in Boston, USA [33]. A total of 1,050 S. pneumoniae
strains were isolated from 1,042 children. Eighty-nine isolates
(8.5%) were identified as one of the 6 additional serotypes
included in PCV13. A fall/winter peak of pneumococcal
carriage of PCV13 serotypes was observed in nonvaccinated
children but was blunted in vaccinated children. The authors
reported a 74% reduction of PCV13 serotype colonization in
the vaccinated children compared to nonvaccinated children.
Approximately >75% community children received PCV13
vaccination, and a >50% decline of PCV13 serotype carriage
was observed in nonimmune children in the same commu-
nity. Consequently, the differences of the PCV13 serotype
colonization between nonvaccinated and vaccinated children
became not significant [33]. In addition, no evidence of
replacement has been observed to date.
In England, the pneumococcal carriage of a group of
children and their families in 2012 and 2013 after the PCV13
implementation was studied and compared with that in two
previous periods, 2001-2002 before the PCV7 introduction
and 2008-2009 after the PCV7 introduction [34]. The preva-
lence of pneumococcal carriage in children <5 years was
similar among these three periods, 47.7% (95% CI, 41.8–
53.5), 51.0% (95% CI, 44.0–58.0), and 48.4% (95% CI, 44.1–
52.7) in 2012-2013, 2008-2009, and 2001/2002, respectively.
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The prevalence of pneumococcal carriage in children of 5–
20-years of age was 22.3% (95% CI, 15.6–30.9) in 2012-
2013 and most strains (22/25, 88.0%) were of non-PCV13
serotypes. Only 3.4% (95% CI, 1.9–6.1) children ≥20 years
of age were positive of pneumococcal carriage in the period
of 2012-2-013, which was lower than that of the last two
periods. Compared to the pneumococcal carriage in 2001-
2002 before the PCV7 introduction, the odds of PCV7
serotype carriage significantly decreased in both 2008-2009
and 2012/2013, while the odds of carriage of the additional
six PCV13 serotypes increased after the PCV7 introduction
but significantly declined after the PCV13 introduction. The
case/carrier ratio (CCR) for the serotypes of the highest
carriage was relatively low. The highest CCR was observed
for serotypes 7F, 19A, 3, 8, and 33F. Across the three carriage
studies, CCR estimates were stable for nearly all serotypes.
6. Conclusions
Despite the difficulties deriving from the differences in
immunization programs, vaccination coverage, the timing of
PCV13 introduction since previous PCV7 implementation,
and the presence/absence of catch-up campaigns, global
evaluation and comparison of the incidence of pneumococcal
diseases in young children who received PCV13 and/or PCV7
suggest that PCV13 provides a wider and more optimal cov-
erage against pneumococcal disease than PCV7. It has been
reported that PCV13 vaccination resulted in significantly
higher effectiveness against IPD, mucosal pneumococcal
diseases, and pneumococcal carriage than PCV7. Given the
high safety and tolerance, PCV13 is an effective conjugate
vaccine for controlling the incidence of pneumococcal dis-
eases. However, PCV13 has been implemented for a relatively
short time and long-term surveillance should be conducted
in the future to further evaluate the safety and effectiveness
of this novel vaccine. First of all, effectiveness against the
additional 6 serotypes covered by PCV13 should be better
defined. If the effectiveness against serotypes 6A, 7F, and 19A
is indisputable, the effectiveness against serotypes 1, 3, and 5
needs further evaluation. Due to the relatively low number of
cases caused by serotypes 1 and 5, no conclusion was drawn
on the effectiveness against these two serotypes between
pre- and post-PCV13 implementation periods. However, the
reduction of the incidence ofCAPwith empyema, a condition
frequently caused by the most invasive serotypes, suggests
that PCV13was highly effective in preventing these pathogens
[24]. It has been reported that the effectiveness of PCV13
against serotype 3 was not satisfactory [14]. Finally, the
replacement phenomenon should be further studied due to
inconsistent results.
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